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Purpose or Objective: Glioblastoma multiforme (GBM) is the 
most common malignant brain tumour in adults. The current 
standard of care includes surgery followed by radiotherapy 
(RT) and chemotherapy with temozolomide (TMZ). Treatment 
often fails due to the radiation and TMZ resistance of a small 
percentage of cells with stem cell-like behavior (CSC). The 
Notch signaling pathway is expressed and active in human 
glioblastoma and Notch inhibitors attenuate tumor growth in 
vivo in xenograft models. Here, we investigate the efficacy of 
a clinically (FDA) approved γ-secretase inhibitor (GSI) 
RO4929097 in tumor control in combination with standard 
care of treatment (TMZ+RT) in an orthotopic glioma tumour 
model.  
 
Material and Methods: Treatment efficacy in vitro was 
tested in 2D cultures using proliferation and clonogenic 
survival assays. 3D sphere assays were used as a model for 
pharmacological treatment response with quantification of 
spheroid growth delay in the different different treatment 
arms. Flow cytometry was used to detect cells expressing 
stem cell markers. Luciferase-expressing U87 cells were 
intracranially injected into the brain of CD-1 mice. Tumor 
volume was quantified using contrast-enhanced microCT and 
bioluminescence imaging. Animals received TMZ (ip), 
RO4929097 (GSI, orally) or radiation (RT, 8Gy) alone or in 
combination. RT dose was calculated and prescribed using 
SmART-Plan software with two 5-mm parallel-opposed beams 
placed at the center of the tumour. 
 
Results: GSI in combination with RT and TMZ attenuated 
tumour cell proliferation, clonogenic survival as well as 
glioma spheroid growth. The expression of glioma stem cell 
markers SOX2 and CD133 was blocked by single or combined 
treatments with Notch inhibitors in vitro. Using our image 
guided micro-CT and radiotherapy platform in vivo, a 
significant growth delay was observed in GSI-, RT- and TMZ-
only treated groups compared to the control group. Standard 
of care treatment (RT + TMZ) or addition of GSI to either TMZ 
or RT irradiation resulted in a significant growth delay and 
prolonged survival. Strikingly, the longest tumour growth 
delay together with an increase in median survival was 
observed in mice treated with the triple combination 
(GSI+RT+TMZ), with 1 out of 4 mice showing tumour cure. 
 
Conclusion: We show in an orthotopic glioblastoma mouse 
model that adding a clinically approved Notch inhibitor to the 
TMZ/RT standard of care results in a significant growth delay 
and increased overall survival. The observed therapeutic 
benefit is promising for clinical translation in order to 
increase survival in patients bearing glioblastoma with active 
Notch signaling. 
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Purpose or Objective: It is well known that PI3K/Akt 
pathway is hyperactivated in K-RAS mutated tumor cells and 
is involved in radioresistance. Exposure to ionizing radiation 
induces activation of DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) as an essential enzyme for repair of DNA 
double-strand breaks (DSBs) through non-homologous end 
joining. Radiation-induced DNA-PKcs activity is partially 
dependent on serine/threonine kinase Akt1. In this study, 
role of DNA-PKcs in Akt1-mediated DSBs repair and post-
irradiation cell survival was investigated. Likewise, a direct 
physical interaction of Akt1 with DNA-PKcs was studied. 
 
Material and Methods: Non-small cell lung cancer cell line 
A549 and colorectal cancer cell line HCT116 with point 
mutations in K-RAS gene were utilized. Complex formation of 
Akt1 with DNA-PKcs and role of Akt1 in DSBs repair were 
tested by immunoprecipitation and γH2AX foci assays, 
respectively. Localization of Akt1 to DSB site was tested by 
immunofluorescence staining and confocal microscopy of P-
Akt (S473) and γH2AX following microbeam laser irradiation 
and after exposure to ionizing radiation. To determine the 
potential interacting domain of Akt1 with DNA-PKcs; GST, 
GST-Akt1 full-length, GST-Akt1-N-terminal fragment (1–150 
a.a.), and GST-Akt1-C-terminal (151–480 a.a.) proteins were 
incubated with purified DNA-PKcs and pull-down assay was 
performed. In order to identify the domain of DNA-PKcs that 
interacts with Akt1, constructs expressing four distinct 
fragments of DNA-PKcs (1-426, 427-1400, 2401-3850, 3700-
4128 a.a) tagged with EGFP and full length Akt1 tagged with 
mCherry were produced. Akt1/DNA-PKcs was studied in A549 
cells, transiently transfected with the appropriate constructs. 
 
Results: Akt1 formed a complex formation with DNA-PKcs in 
the nuclear fraction immediately after irradiation. Nuclear 
Akt1 was co-localized with γH2AX foci and found to be 
essential for the efficient repair of ionizing radiation-induced 
DSBs and post-irradiation cell survival, in a DNA-PKcs 
dependent manner. A direct physical interaction of DNA-PKcs 
to the C-terminal domain of Akt1 could be demonstrated. 
Additionally, Akt1 was found to make physical interaction not 
only with the C-terminal domain of DNA-PKcs (3700-4188 
a.a.) but also with the N-terminal domain (1-426 a.a.). 
 
Conclusion: Akt1, through a direct physical interaction with 
DNA-PKcs, regulates repair of ionizing radiation-induced 
DSBs. Thus, due to overexpression of Akt1 in tumor cells and 
constitutive Akt activity in K-RAS mutated tumors cells, Akt1 
can be proposed as a tumor specific target for 
radiosensitization. 
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Purpose or Objective: Total mesorectal excision is the 
cornerstone of rectal cancer treatment and preoperative 
(chemo)radiotherapy and adjuvant chemotherapy are often 
administered. This population-based study compares the 
survival in clinical stage I-III rectal cancer patients who 
received either preoperative radiotherapy, preoperative 
chemoradiotherapy or no preoperative therapy. The effect of 
type of radical resection and adjuvant chemotherapy on 
survival was also investigated. 
 
Material and Methods: Patients diagnosed between January 
2006 and December 2011 with clinical stage I-III rectal 
adenocarcinoma were retrieved from the national Cancer 
Registry database. Only first primary invasive rectal tumors 
were included and only patients who underwent a radical 
resection were retained. The observed survival was 
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calculated from the date of surgery until the date of death or 
until the last known vital status. Conditional survival was 
defined as the survival conditional on surviving one year after 
surgery and was calculated in order to avoid the impact of 
adverse events in the postoperative course.  
Multivariable Cox proportional-hazards regression models 
were applied to evaluate the association of preoperative 
treatment, type of radical resection and use of adjuvant 
chemotherapy with survival, adjusting for the baseline 
characteristics age, gender, WHO score and clinical stage.  
 
Results: A total of 5173 eligible rectal cancer patients were 
identified from the national database. Preoperative 
treatment was as follows: none in 1354 (26.2%), radiotherapy 
in 797 (15.4%) and chemoradiotherapy in 3022 (58.4%) 
patients. Patients who received no preoperative therapy or 
preoperative radiotherapy and those who underwent 
abdominoperineal resection had a lower observed survival as 
compared with patients receiving preoperative 
chemoradiotherapy or treated with sphincter-sparing surgery 
respectively (Table). The patient group receiving adjuvant 
chemotherapy had a worse observed survival than the group 
receiving no adjuvant therapy. These effects were age-
dependent. Multivariable analysis demonstrated similar 
findings for the observed survival conditional on surviving the 
first year after surgery. 
 
Conclusion: In this population-based study, preoperative 
chemoradiotherapy, sphincter-sparing surgery and no 
adjuvant chemotherapy were associated with a superior 
survival in clinical stage I-III rectal cancer patients. 
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Purpose or Objective: To model acute hematologic toxicity 
(HT) and dose to pelvic osseous structures in anal cancer 
patients treated with definitive chemo-radiation (CT-RT). 
 
Material and Methods: 53 patients receiving CT-RT were 
analyzed. Pelvic bone marrow (PBM) and corresponding 
subsites were contoured: ilium (IBM), lower pelvis (LPBM) and 
lumbosacral spine (LSBM). Dose-volume histograms points and 
mean doses were collected. Logistic regression was 
performed to correlate dosimetric parameters and > G2-G3 
HT as endpoint. Normal tissue complication probability 
(NTCP) was evaluated with the Lyman-Kutcher-Burman (LKB) 
model. 
 
Results: Logistic regression showed a significant correlation 
between LSBM mean dose and >G2 neutropenia (β 
coefficient:0.109;p=0.037;95%CI:0.006-0.212) and >G3 
leukopenia (β coefficient:0.122; p=0.030;95% CI:0.012-0.233) 
(Table 1). According to NTCP modeling, the predicted HT 
probability had the following parameters: TD50:32.6 Gy, 
γ50:0.89, m:0.449 (>G2 neutropenia) and TD50:37.5 Gy, 
γ50:1.15, m:0.347 (>G3 leukopenia) (Figure 1). For node 
positive patients TD50:30.6 Gy, γ50:2.20, m:0.181 (>G2 
neutropenia) and TD50:35.2 Gy, γ50:2.27, m:0.176 (>G3 
leukopenia) were found (Figure 1) 
 
 
.  
Node positive patients had significantly higher PBM-V15 
(Mean:81.1%vs86.7%;p=0.04), -V20 
(Mean:72.7%vs79.9%;p=0.01) and V30 
(Mean:50.2%vsMean:57.3%;p=0.03).Patients with a mean 
LSBM dose >32 Gy had a 1.31 (95%CI:0.75-2.35) and 1.81 
(95%CI:0.81-4.0) relative risk to develop >G2 neutropenia and 
>G3 leukopenia. For node positive patients those risks were 
1.67 (95%CI:0.76-3.64) and 2.67 (95%CI:0.71-10).To have a 
<5%, <10%,<20% risk to develop >G2 neutropenia and >G3 
leukopenia, LSBM mean dose should be below 6 Gy, 13 Gy and 
20 Gy and 14 Gy, 20 Gy and 26 Gy, respectively. For node 
positive patients these thresholds were below 21 Gy, 23 Gy 
